DOI | Resolve DOI: https://doi.org/10.1021/jz201664h |
---|
Author | Search for: Das, Gautom Kumar; Search for: Johnson, Noah J. J.; Search for: Cramen, Jordan; Search for: Blasiak, Barbara1; Search for: Latta, Peter1; Search for: Tomanek, Boguslaw1; Search for: van Veggel, Frank C. J. M. |
---|
Affiliation | - National Research Council of Canada. NRC Institute for Biodiagnostics
|
---|
Format | Text, Article |
---|
Abstract | A major limitation of the commonly used clinical MRI contrast agents (CAs) suitable at lower magnetic field strengths (<3.0 T) is their inefficiency at higher fields (>7 T), where next-generation MRI scanners are going. We present dysprosium nanoparticles (β-NaDyF4 NPs) as T2 CAs suitable at ultrahigh fields (9.4 T). These NPs effectively enhance T2 contrast at 9.4 T, which is 10-fold higher than the clinically used T2 CA (Resovist). Evaluation of the relaxivities at 3 and 9.4 T show that the T2 contrast enhances with an increase in NP size and field strength. Specifically, the transverse relaxivity (r2) values at 9.4 T were 64 times higher per NP (20.3 nm) and 6 times higher per Dy3+ ion compared to that at 3 T, which is attributed to the Curie spin relaxation mechanism. These results and confirming phantom MR images demonstrate their effectiveness as T2 CAs in ultrahigh field MRIs. |
---|
Publication date | 2012-02-03 |
---|
In | |
---|
Language | English |
---|
Peer reviewed | Yes |
---|
NPARC number | 21268894 |
---|
Export citation | Export as RIS |
---|
Report a correction | Report a correction (opens in a new tab) |
---|
Record identifier | a08cbca3-f8a0-4521-a3ff-7971d8034220 |
---|
Record created | 2013-11-22 |
---|
Record modified | 2020-04-21 |
---|